Natália Maria Valeriano da Silva
Natália Maria Valeriano da Silva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- João Eduardo Cordeiro Ferreira dos Santos1 shared publication
- Laysla Tamyres de Oliveira Borges1 shared publication
- Maria Clara Gomes Oliveira1 shared publication
- Mariana Gaspar Côrte Real1 shared publication
- Milena Marcia da Silva1 shared publication
- Patricia Cristina de Veras Souza Maia
University Federal Rural of Pernambuco
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by Revista ft Ltda in Revista ft
- Vol. 30 (164) , 01-11
DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.
Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.
- 1 November 2026
- Published by Revista ft Ltda in Revista ft
- Vol. 30 (164) , 01-11
Open AccessDNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.
Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.